Development
Thermo Fisher Scientific Inc.
TMO
$414.90
$0.17980.04%
NYSE
| 12/31/2023 | 09/30/2023 | 07/01/2023 | 04/01/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -13.74% | -15.51% | -23.09% | -20.77% | -10.03% |
| Total Depreciation and Amortization | 0.74% | 6.19% | 13.11% | 19.47% | 30.44% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -257.81% | -89.51% | -31.80% | -108.29% | -123.57% |
| Change in Net Operating Assets | 48.81% | 49.86% | 13.64% | -54.90% | 32.24% |
| Cash from Operations | -8.17% | 0.57% | -12.95% | -19.45% | -1.70% |
| Capital Expenditure | 34.06% | 35.66% | 26.47% | 18.70% | 11.10% |
| Sale of Property, Plant, and Equipment | 262.50% | 182.76% | -31.03% | 64.71% | 20.00% |
| Cash Acquisitions | -9,284.62% | 79.57% | 84.73% | 85.06% | 99.80% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -190.91% | -205.95% | -201.18% | 1,650.00% | 391.18% |
| Cash from Investing | -138.17% | 73.97% | 77.18% | 77.52% | 90.16% |
| Total Debt Issued | 60.25% | -54.29% | -75.52% | -75.93% | -77.15% |
| Total Debt Repaid | -89.84% | 69.73% | 79.37% | 72.05% | 65.37% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 0.00% | -90.39% | -90.39% | -90.39% | -42.79% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -14.95% | -14.29% | -14.59% | -14.11% | -15.19% |
| Other Financing Activities | 722.22% | 24.00% | -83.56% | 309.09% | -113.85% |
| Cash from Financing | -28.90% | -93.97% | -128.02% | -127.25% | -142.70% |
| Foreign Exchange rate Adjustments | 41.01% | 188.76% | 170.37% | -69.05% | -171.65% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -110.87% | 135.48% | 124.33% | 125.53% | 169.22% |